{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:59:06Z","timestamp":1778716746504,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06666-7","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T02:33:16Z","timestamp":1759977196000},"page":"4771-4778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cB\u201d symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6463-7543","authenticated-orcid":false,"given":"Karolina","family":"Chromik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Wieczorkiewicz-Kabut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrycja","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kocl\u0119ga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Kad\u0142ubek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Kami\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"6666_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3109\/10428194.2013.815353","volume":"55","author":"ED Hsi","year":"2014","unstructured":"Hsi ED, Martin P (2014) Indolent mantle cell lymphoma. Leuk Lymphoma 55:761\u2013767","journal-title":"Leuk Lymphoma"},{"key":"6666_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I (2022) The 5th edition of the world health organization classification of haematolymphoid tumors: lymphoid neoplasms. Leukemia 36:1720\u20131748","journal-title":"Leukemia"},{"key":"6666_CR3","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","volume":"115","author":"CH Geisler","year":"2010","unstructured":"Geisler CH, Kolstad A, Laurell A et al (2010) The mantle cell lymphoma international prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115:1530\u20131533","journal-title":"Blood"},{"key":"6666_CR4","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME et al (2013) Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 31:3688\u20133695","journal-title":"J Clin Oncol"},{"key":"6666_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JCO.18.00690","volume":"37","author":"JN Gerson","year":"2019","unstructured":"Gerson JN, Handorf E, Villa D et al (2019) Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol 37:471\u2013480","journal-title":"J Clin Oncol"},{"key":"6666_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.881346","volume":"12","author":"H Liu","year":"2022","unstructured":"Liu H, Shi X, Fang H (2022) First-line autologous stem cell transplantation for mantle cell lymphoma: a systematic analysis and treatment recommendation. Front Oncol 12:881346","journal-title":"Front Oncol"},{"key":"6666_CR7","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E et al (2024) Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European mantle cell lymphoma network. Lancet 403:2293\u20132306","journal-title":"Lancet"},{"key":"6666_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hilden P, Coiffier B et al (2017) International working group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 28:1436\u20131447","journal-title":"Ann Oncol"},{"key":"6666_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/ejh.13985","volume":"111","author":"B Metzner","year":"2023","unstructured":"Metzner B, M\u00fcller TH, Casper J et al (2023) Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol 111:220\u2013228","journal-title":"Eur J Haematol"},{"key":"6666_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hon.2952","volume":"40","author":"A Mathys","year":"2022","unstructured":"Mathys A, Bacher U, Banz Y et al (2022) Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era. Hematol Oncol 40:292\u2013296","journal-title":"Hematol Oncol"},{"key":"6666_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e19043","volume":"42","author":"M Maranzano","year":"2024","unstructured":"Maranzano M, Saha A, Timmerman J (2024) Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California cancer registry (CCR). JCO 42:19043","journal-title":"JCO"},{"key":"6666_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558\u2013565","journal-title":"Blood"},{"key":"6666_CR13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","volume":"32","author":"E Hoster","year":"2014","unstructured":"Hoster E, Klapper W, Hermine O et al (2014) Confirmation of the Mantle-Cell lymphoma international prognostic index in randomized trials of the European Mantle-Cell lymphoma network. JCO 32:1338\u20131346","journal-title":"JCO"},{"key":"6666_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML (2022) Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 97:638\u2013656","journal-title":"Am J Hematol"},{"key":"6666_CR15","doi-asserted-by":"publisher","first-page":"16180","DOI":"10.1097\/MD.0000000000016180","volume":"98","author":"H Haydaroglu Sahin","year":"2019","unstructured":"Haydaroglu Sahin H (2019) Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts? Medicine (Baltimore) 98:16180","journal-title":"Medicine (Baltimore)"},{"key":"6666_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/09636897231179364","volume":"32","author":"R Wu","year":"2023","unstructured":"Wu R, Ma L (2023) BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as conditioning regimen before autologous haematopoietic cell transplantation: a systematic review and meta analysis. Cell Transplant 32:09636897231179364. https:\/\/doi.org\/10.1177\/09636897231179364","journal-title":"Cell Transplant"},{"issue":"2 Suppl","key":"6666_CR17","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/S2666-6367(23)00278-6","volume":"29","author":"JM Carranza","year":"2023","unstructured":"Carranza JM, Fatobene G, Cordeiro AC et al (2023) Incidence of early toxicities and mortality after four types of conditioning regimens for autologous hematopoietic cell transplantation in patients with lymphoma: impact of National drug shortages in a resource-constrained country. Transplant Cell Ther 29(2 Suppl):S162\u2013S163","journal-title":"Transplant Cell Ther"},{"key":"6666_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507\u2013516","journal-title":"N Engl J Med"},{"key":"6666_CR19","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M et al (2022) Ibrutinib plus bendamustine and rituximab in untreated Mantle-cell lymphoma. N Engl J Med 386:2482\u20132494","journal-title":"N Engl J Med"},{"key":"6666_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/hematology.2024000546","volume":"6","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Dreyling M (2024) To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL. Hematol Am Soc Hematol Educ Program 6:42\u201347","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06666-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06666-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06666-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:30Z","timestamp":1761283830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06666-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6666"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06666-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted using anonymized patient data. According to the guidelines of the Ethics Committee, formal ethical approval was not required. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients and is available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}